Value-based healthcare: What’s it worth to you?It takes healthy people to make a healthy society – and that must be taken into account when Share XValue-based healthcare: What’s it worth to you?https://pharmaphorum.com/views-and-analysis/value-based-healthcare-whats-worth/
Brexit from the inside: MP’s views on how it will impact pharmaWith the potential for a hard-no-deal Brexit becoming closer to reality with each passing day, the question of Share XBrexit from the inside: MP’s views on how it will impact pharmahttps://pharmaphorum.com/views-and-analysis/brexit-inside-mps-views-impact-pharma/
Division on European HTAThere have been aspirations for closer collaboration between European Union (EU) Member States (MS) on Health Technology Assessment Share XDivision on European HTAhttps://pharmaphorum.com/views-and-analysis/hta-european-health-technology-assessment-division-progress/
The NHS and integrated care systems – how can pharma play its part?The concept of joining up health and social care has been around a long time – but now Share XThe NHS and integrated care systems – how can pharma play its part?https://pharmaphorum.com/views-analysis-market-access/nhs-integrated-care-systems/
Live Well: when health and opportunity knocksLive Well brings health products to the doorsteps of rural Zambians in an innovative partnership between GSK and Share XLive Well: when health and opportunity knockshttps://pharmaphorum.com/views-analysis-market-access/live-well-health-and-opportunity-knocks/
Biosimilar switches and healthcare gainsDespite being used across Europe for more than a decade, biosimilar medications are still something of a mystery Share XBiosimilar switches and healthcare gainshttps://pharmaphorum.com/market-access-2/biosimilar-switches-and-healthcare-gains/
Matt Hancock has big shoes to fill as he takes over from Jeremy HuntWhat changes will the appointment of Matt Hancock MP as Secretary of State for Health and Social Care mean for the Share XMatt Hancock has big shoes to fill as he takes over from Jeremy Hunthttps://pharmaphorum.com/market-access-2/matt-hancock-jeremy-hunt-department-health/
Who should pay for HTA?Part of the drive for strengthening EU cooperation on health technology assessment (HTA) is to tackle duplication of Share XWho should pay for HTA?https://pharmaphorum.com/views-analysis-digital/who-should-pay-hta/
Patient centricity makes ethical and commercial sensePatient centricity is no longer a buzzword, it’s an essential way of conducting business that makes both ethical Share XPatient centricity makes ethical and commercial sensehttps://pharmaphorum.com/views-analysis-market-access/patient-centricity-makes-ethical-and-commercial-sense/
